arrow
M

Margareth C. Ozelo

university of california–san francisco
H指数:34
被引数:7,192

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study

在非研究性产品研究中对血友病A和B患者出血率和因子使用情况进行前瞻性收集

2026-08-010
PRE
Impact of Fidanacogene Elaparvovec Gene Therapy on Joint Health in Adults With Haemophilia B: Results From a Phase 3 Study

Fidanacogene Elaparvovec基因疗法对血友病B成人患者关节健康的影响:一项3期研究的结果

2025-11-010
PRE
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025

《WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025》

2025-10-250
OAAI
Global Comparative Antithrombin Field Study: Impact of Laboratory Assay Variability on the Assessment of Antithrombin Activity Measurement at Fitusiran Clinical Decision-Making Points

全球抗凝血酶比较性现场研究:实验室检测变异对评估抗凝血酶活性测量在Fitusiran临床决策点的影响

2025-04-200
OAAI
Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance

使用糖皮质激素以减轻valoctocogene roxaparvovec基因治疗后与转氨酶升高相关的FVIII水平下降:临床实践指南

2025-03-140
OAAI
Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study

valoctocogene roxaparvovec联合预防性糖皮质激素的安全性及有效性:来自3b期、单臂、开放标签GENEr8-3研究的1年结果

2025-01-011
PRE
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024-12-090
PRE
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal
2024-12-060
PREAI
Immune Mechanisms and Cytokine Profiles in Hemophilia a Patients Undergoing Low-Dose ITI and Emicizumab Prophylaxis: Implications for ITI Success and Failure

免疫机制和细胞因子谱在低剂量ITI和emicizumab预防治疗的血友病A患者中的表现:对ITI成功与失败的启示

BLOOD
IF23.1
2024-11-050
PRE
Utilizing artificial intelligence for the detection of hemarthrosis in hemophilia using point-of-care ultrasonography

利用人工智能通过护理点超声检查检测血友病中的关节积血

2024-11-010
OAAI
Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial

在3期GENEr8-1试验中,valoctocogenene roxaparvovec基因转移治疗严重血友病A后4年的疗效,安全性和生活质量

2024-11-010
OAAI
The translational gap for gene therapies in low- and middle-income countries
2024-05-084
OA